COSCIENS Biopharma Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de COSCIENS Biopharma.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	32.8%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

May 10

We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Nov 12

Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Jul 15

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Mar 29

Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Feb 04

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como COSCIENS Biopharma no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

TSX:CSCI - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	5	-23	-27	-27	N/A
6/30/2024	5	-18	-19	-19	N/A
3/31/2024	4	-18	-19	-19	N/A
12/31/2023	4	-17	-17	-17	N/A
9/30/2023	6	-18	-8	-8	N/A
6/30/2023	8	-17	-9	-9	N/A
3/31/2023	7	-20	-13	-13	N/A
12/31/2022	6	-23	-14	-14	N/A
9/30/2022	4	-13	-13	-13	N/A
6/30/2022	3	-12	-10	-10	N/A
3/31/2022	5	-10	-9	-9	N/A
12/31/2021	5	-8	-9	-9	N/A
9/30/2021	7	-7	-4	-4	N/A
6/30/2021	6	-6	-4	-4	N/A
3/31/2021	4	-7	-3	-3	N/A
12/31/2020	4	-5	-4	-4	N/A
9/30/2020	1	-5	-10	-10	N/A
6/30/2020	1	-4	-10	-10	N/A
3/31/2020	2	0	-10	-10	N/A
12/31/2019	1	-6	-11	-11	N/A
9/30/2019	2	-10	-10	-10	N/A
6/30/2019	2	-12	-10	-10	N/A
3/31/2019	2	-15	-13	-13	N/A
12/31/2018	27	4	7	7	N/A
9/30/2018	26	9	5	5	N/A
6/30/2018	25	2	N/A	2	N/A
3/31/2018	25	2	N/A	1	N/A
12/31/2017	1	-17	N/A	-23	N/A
9/30/2017	1	-25	N/A	-27	N/A
6/30/2017	1	-21	N/A	-27	N/A
3/31/2017	1	-25	N/A	-27	N/A
12/31/2016	1	-25	N/A	-29	N/A
9/30/2016	1	-27	N/A	-29	N/A
6/30/2016	1	-36	N/A	-31	N/A
3/31/2016	1	-44	N/A	-33	N/A
12/31/2015	1	-50	N/A	-34	N/A
9/30/2015	0	-36	N/A	-34	N/A
6/30/2015	0	-32	N/A	-33	N/A
3/31/2015	0	-23	N/A	-32	N/A
12/31/2014	0	-17	N/A	-31	N/A
9/30/2014	N/A	-32	N/A	-19	N/A
6/30/2014	0	-28	N/A	-21	N/A
3/31/2014	0	-33	N/A	-24	N/A
12/31/2013	6	-27	N/A	-20	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de CSCI es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de CSCI crezcan más rápidamente que el mercado Canadian

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de CSCI crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de CSCI crezcan más rápidamente que el mercado de Canadian.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de CSCI crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CSCI se prevé que sea elevada dentro de 3 años.

COSCIENS Biopharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

New major risk - Market cap size

Third quarter 2024 earnings released: US$1.85 loss per share (vs US$3.41 loss in 3Q 2023)

COSCIENS Biopharma Inc. Announces Resignation of Carolyn Egbert from the Board of Directors

Cosciens Biopharma Inc. Announces Directorate Changes

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT- Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Second quarter 2024 earnings released: US$0.64 loss per share (vs US$2.07 loss in 2Q 2023)

Aeterna Zentaris Inc. Announces the Resignation of Peter G. Edwards as Director

Aeterna Zentaris Inc. (TSX:AEZS) completed the acquisition of Ceapro Inc. (TSX:AEZS) in a merger of equals transaction.

Aeterna Zentaris Inc., Annual General Meeting, Jul 02, 2024

Aeterna Zentaris Inc. (TSX:AEZS) entered into a definitive agreement to acquire Ceapro Inc. (TSXV:CZO) for CAD 21.4 million in a merger of equals.

Aeterna Zentaris Inc. Provides an Update on Its Therapeutic and Diagnostic Development Pipeline Programs and Outlined Upcoming Key Milestones

Aeterna Zentaris Announces Effective Date of Share Consolidation

Aeterna Zentaris Inc., Annual General Meeting, Jul 15, 2022

Aeterna Zentaris Inc., Annual General Meeting, Jul 06, 2022

Aeterna Zentaris Inc. Achieves Proof-Of-Concept for the Treatment of NMOSD with AIM Biologicals Program

Aeterna Zentaris’ Licensing Partner, Consilient Health Announces European Launch of Ghryvelin™ (Macimorelin) for Diagnosing Adult Growth Hormone Deficiency

Aeterna Zentaris Inc. Updates on Positive Pre-Clinical Results from Aim Biologicals Development Program for the Potential Treatment of Parkinson's Disease

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Hopeful That Aeterna Zentaris (TSE:AEZS) Will Use Its Cash Wisely

Aeterna Zentaris Inc., Annual General Meeting, Jun 21, 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Aeterna Zentaris Receives 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

We're Interested To See How Aeterna Zentaris (TSE:AEZS) Uses Its Cash Hoard To Grow

Third quarter 2021 earnings released: US$0.014 loss per share (vs US$0.02 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.15 loss in 2Q 2020)

Aeterna Zentaris Inc. Provides Update on Its Pre-Clinical and Clinical Development Programs

Here's Why We're Not At All Concerned With Aeterna Zentaris' (TSE:AEZS) Cash Burn Situation

Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit

Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)

Aeterna Zentaris Inc. Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency

Independent Director has left the company

Aeterna Zentaris Announces the Selection of A Development Candidate in the DC-PTH Program for the Potential Treatment of Primary Hypoparathyroidism

First quarter 2021 earnings released: US$0.015 loss per share (vs US$0.036 profit in 1Q 2020)

Companies Like Aeterna Zentaris (TSE:AEZS) Can Afford To Invest In Growth

Full year 2020 earnings released: US$0.13 loss per share (vs US$0.34 loss in FY 2019)

Aeterna Zentaris Inc., Annual General Meeting, May 05, 2021

New 90-day high: CA$1.37

Reflecting on Aeterna Zentaris' (TSE:AEZS) Share Price Returns Over The Last Five Years

Aeterna Zentaris Inc. Enters into an Exclusive Option Agreement to Evaluate Preclinical Potential COVID-19 Vaccine Developed at the Julius-Maximilians-University Wuerzburg

Aeterna Zentaris Expands Orphan Drug Development Pipeline with Targeted Immunosuppressive Therapeutics

The Nasdaq Stock Market LLC Grants an Additional 180 Calendar-Day Period Extension to Aeterna Zentaris to Regain Compliance with Minimum Bid Price Rule

New 90-day high: CA$0.90

New 90-day high: CA$0.66

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

Aeterna Zentaris Inc. Amends License Agreement with Novo Nordisk for Commercialization and Development of Macimorelin

New 90-day low: CA$0.39

Third quarter 2020 earnings released: US$0.02 loss per share

New 90-day low: CA$0.46

The Rosen Law Firm, P.A. and Glancy Prongay & Murray LLP Announce Proposed Class Action Settlement on Behalf of Purchasers of Securities of Aeterna Zentaris, Inc

Aeterna Zentaris Inc. Announces Macimorelin Clinical Program Update

New 90-day low - CA$0.49

First half earnings released

Aeterna Zentaris Inc. has completed a Follow-on Equity Offering in the amount of $7.000001 million.

Aeterna Receives Nasdaq Warning on Minimum Price

Aeterna Zentaris Inc. has completed a Composite Units Offering in the amount of $11.999087 million.

Aeterna Zentaris Inc.(NasdaqCM:AEZS) dropped from Russell Microcap Value Index

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento